The ADANCE [ Apixaban Versus Dual-antiplatelet Therapy ( Clopidogrel and Aspirin ) in Acute Non-disabling Cerebrovascular Events ] study is a randomized , double-blind clinical trial with a target enrollment of 5,500 patients .